Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BIIB 080

Next Previous
Drug Profile

BIIB 080

Alternative Names: BIIB080; IONIS BIIB4RX; IONIS MAPTRx; IONIS-MAPTRX; ISIS 814907

Latest Information Update: 15 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ionis Pharmaceuticals
  • Developer Biogen; Ionis Pharmaceuticals
  • Class Antidementias; Antisense oligonucleotides; Neuroprotectants
  • Mechanism of Action Gene silencing; Tau protein expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alzheimer's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 02 Apr 2025 BIIB 080 receives Fast Track designation for Alzheimer's disease [Intrathecal,Injection] in USA
  • 30 Jan 2025 Biogen initiated phase I trial (In volunteers) in June 2024 (Intrathecal, injection) (NCT06454721)
  • 07 Nov 2024 Biogen completes enrolment in the phase II CELIA trial in Alzheimer's disease in US, Canada, Japan, Australia, Belgium, Denmark, Germany, Italy, Poland, Spain, Switzerland, United Kingdom (Intrathecal) (NCT05399888)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top